Showing 1501-1510 of 1635 results for "".
- Think About Your Eyes Launches Enhanced Websitehttps://modernod.com/news/think-about-your-eyes-launches-enhanced-website/2477258/Think About Your Eyes, a national public awareness campaign by The Vision Council and the American Optometric Association, announced the launch of its new website. Featuring new content and a modern, easy-to-navigate design, the new platform provides information on eye health, eye conditions, vis
- Hoya Surgical Optics Launches Joint Venture With GeMax in Chinahttps://modernod.com/news/hoya-surgical-optics-launches-joint-venture-with-gemax-in-china/2477238/Hoya Surgical Optics (HSO) announced a new joint venture with GeMax, a specialty promotion service provider of IOLs with a strong market position and reputation in China, covering more than 630 major hospitals in 32 provinces. The joint venture will be named Hoya GeMax Medical. HSO will be the ma
- Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry AMDhttps://modernod.com/news/gemini-therapeutics-enrolls-first-patient-in-phase-1-study-of-gem103-for-dry-amd/2477214/Gemini Therapeutics announced it has initiated enrollment in its phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of
- Laundry Pods Cause Growing Number of Eye Injuries in U.S.https://modernod.com/news/laundry-pods-cause-growing-number-of-eye-injuries-in-u-s/2477198/A growing number of kids are getting chemicals from laundry detergent pods in their eyes, even as ocular injuries from other types of household cleaners steadily decline, a U.S. study suggests, Reuters reported. Nationwide, poison c
- Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Diseasehttps://modernod.com/news/nicoxs-ncx-4251-meets-primary-endpoint-in-phase-2-blepharitis-trial-and-shows-promising-efficacy-in-dry-eye-disease/2477187/Nicox SA announced that NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, has met the primary objective of its U.S. multicenter, dose escalating, first-in-human, phase 2 clinical trial (referred to as ‘Danube’) evaluating the safety and tolerability of NCX 4
- The American Optometric Association Urges Employers to Pledge to Make 2020 the Year of the Eye Examhttps://modernod.com/news/the-american-optometric-association-urges-employers-to-pledge-to-make-2020-the-year-of-the-eye-exam/2477180/As part of the American Optometric Association’s (AOA) #2020EyeExam initiative, the organization and doctors of optometry nationwide are calling upon visionary companies across the country to join the 2020 Employer Pledge program–affirming the importance of caring for the overall health and
- NIH Launches First U.S. Clinical Trial of Patient-Derived Stem Cell Therapy to Replace Dying Cells in Retinahttps://modernod.com/news/nih-launches-first-u-s-clinical-trial-of-patient-derived-stem-cell-therapy-to-replace-dying-cells-in-retina/2477175/Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD). Geographic atrophy currently has no treatment.
- Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-trading-halted-today-fda-committee-meeting-to-discuss-teprotumumab-for-thyroid-eye-disease/2477167/Horizon Therapeutics announced that NASDAQ has halted trading of the company’s common stock, listed as HZNP. As per the FDA guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 am to 4 pm ET to discuss
- Mark McGrath to Headline Celebration at Optometry’s Meeting 2020https://modernod.com/news/mark-mcgrath-to-headline-celebration-at-optometrys-meeting-2020/2477126/The American Optometric Association has announced that it is celebrating the decade of the 90s at its annual Optometry’s Meeting, June 24-28, in National Harbor, Maryland/Washington, D.C. “Mark McGrath’s ’90s Experience” will headline the closing Celebration o
- Johnson & Johnson Vision Announces Availability of Acuvue Oasys with Transitions Light Intelligent Technology in the UKhttps://modernod.com/news/johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-uk/2477102/Johnson & Johnson Vision announced the national availability of Acuvue Oasys with Transitions Light Intelligent Technology in the UK. The first-of-its-kind photochromic contact lens offers superior visual performance indoor and outdoor, day and night, according to a company news release.